An interventional study of Home-based Care Monitoring and Aflibercept 2Mg/0.05Ml Inj,Oph in Diabetic Macular Edema, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Retinopathy · Zhongshan Ophthalmic Center, Sun Yat-sen University.
Among the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, this one is one of 2 that started in 2024, is one of 4 with no phase, and was the 7th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →7 of the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18+
Zhongshan Ophthalmic Center, Sun Yat-sen University
Ages 7+ · Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18–80 · Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 40–90
By country, each count listing its studies:
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 308 is above the median of 80 across 484 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 201 across the 4 interventional studies, 2,269 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 165 studies on the registry; 81 are open to participants now.
2 of the studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06272565Zhongshan Ophthalmic Center, Sun Yat-sen UniversityExploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage | 2026-12-30 |
| NCT06610747Zhongshan Ophthalmic Center, Sun Yat-sen UniversityHome- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world. Most patients with DME and vision loss require pharmacological inhibition using anti-VEGF agents with multiple monitoring visits that require both visual acuity testing and optical coherence tomography (OCT) to determine if re-treatment is warranted as well as the recommended time interval to the next follow-up visit. However, this treatment regimen often requires monthly or every other month clinic visits, which places a substantial burden on ophthalmic clinics and patients.
Recently, portable self-administered Home OCT devices have been developed that allow for home-based OCT scanning of retinal diseases, e.g., DME, although these devices do not include visual acuity determination. The investigators previously proposed to deliver Home OCT devices and Home visual acuity tester to patients\' homes to complete routine monitoring visits at home. However, there is a lack of evidence regarding the safety and efficacy of this novel monitoring regimen for DME patients, specifically whether its use could reduce the burden associated with frequent hospital visits without sacrificing visual acuity outcomes.
This study aims to provide evidence to support use of a novel monitoring regimen for DME patients that could substantially reduce the burden associated with frequent hospital visits without sacrificing visual acuity outcomes.
This visit and treatment burden is associated with poorer DME treatment outcomes in the clinical practice (real world) setting compared with outcomes in clinical trials. Studies have shown that less than half of DME patients remain compliant with their anti-VEGF treatment schedules in the clinical practice setting, with many experiencing worse visual acuity levels after missed appointments. Potential reasons for suboptimal outcomes include under-treatment when otherwise indicated, missed visits when treatment should be applied, absence of protocol refractions and protocol visual acuity measurements which may guide treatment but be difficult to obtain in clinic, and anti-VEGF costs. Addressing these challenges could benefit from a novel approach of monitoring patients remotely so that visits only would be needed when treatment was warranted based on changes in best corrected visual acuity or OCT central subfield thickness measurements, but only if this approach does not sacrifice visual acuity outcomes. In particular, reducing the frequency of clinic visits might improve patient compliance and potentially improve treatment outcomes.
To address these challenges, new devices, which currently are not readily available around the world, and new agents or anti-VEGF delivery devices have been developed to try to reduce the burden of injections without sacrificing visual acuity outcomes. However, most of these new agents that could be given q8 or q12 or q16 weeks in some study participants provided non-inferior visual acuity outcomes only in the setting of protocols that included q4week clinic assessments. Potentially, this frequent monitoring may be needed to avoid sacrificing visual acuity outcomes when reducing the number of injections. Furthermore, new delivery devices have been fraught with safety concerns.
Recently, portable self-administered Home OCT devices have been developed that allow for home-based OCT scanning of retinal diseases, e.g., DME, nAMD, or CNV associated with pathologic myopia. The image quality and accuracy of retinal thickness measurements obtained from some of these devices have been validated through comparison with clinic- or hospital-based OCTs, although evaluation of these devices has not included home monitoring of visual acuity, nor determined if their use results in non-inferior visual acuity outcomes.
In this study, the investigators will conduct a non-inferiority randomized clinical trial to determine if the mean change in visual acuity (primary outcome) is non-inferior with the home monitoring of visual acuity and OCT compared with hospital/clinic-based care among DME participants receiving anti-VEGF therapy, and if it is non-inferior, to determine if the home care model can reduce hospital/clinic visits over 96 weeks (principal secondary outcome).
Participants will receive five q4week loading anti-VEGF injections after enrollment. Only those participants who receive loading injections as planned will be assigned randomly to one of two groups and undergo as needed (pro-re-nata, PRN) treatments with injections of anti-VEGF:
Re-injections of anti-VEGF (PRN), laser, surgery or other procedures will be performed per protocol for participants from both groups.
Participant-level Criteria:
Inclusion Criteria:
To be eligible, the following inclusion criteria must be met:
Exclusion Criteria:
An individual is not eligible if any of the following exclusion criteria are present:
Study eye-level Criteria:
The participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below. Participants can have only one study eye. If both eyes are eligible at the time of enrollment and one of the eyes has never received anti-VEGF treatment, that eye should be included. If both eyes are eligible and have previously received anti-VEGF treatment or both eyes have never received anti-VEGF, then the better-seeing eye will be selected before enrollment. If neither eligible eye is the better-seeing eye, then the investigator and participant will select the study eye by mutual agreement before enrollment.The definition of better-seeing, worse-seeing and same eye is in the followings:
The eligibility criteria for a study eye are as follows:
Inclusion Criteria:
Exclusion Criteria:
The following exclusions apply to the study eye only (i.e., they may be present for the non-study eye):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Home-based monitoring with home visual acuity tester and home OCT: For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol.
Procedure: Home-based Care Monitoring · Drug: Aflibercept 2Mg/0.05Ml Inj,Oph · Procedure: Laser Treatment
Standard hospital/clinic-based visual acuity and OCT monitoring: For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol.
Drug: Aflibercept 2Mg/0.05Ml Inj,Oph · Procedure: Laser Treatment · Procedure: Standard Hospital/clinic-based Care Monitoring
For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. The results of the visual acuity and OCT measurements will be transmitted to the clinician at the hospital. An online discussion between the clinician and the participant will be held. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
Drug page: AfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
Also known as: Aflibercept 2-mg/0.05mL intravitreal ophthalmic injection
Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the \'pro re nada\' (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. A discussion between the clinician and the participant will be held in clinic. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
Change in best-corrected visual acuity (letter score) in the study eyes from the randomization visit to 96 week visit
The randomization visit is defined as the visit of the 5th loading dose. Best-corrected visual acuity (letter score) will be measured by masked optometrists using the ETDRS tumbling-E eye chart. The testing procedures are detailed in the study protocol.
Time frame: From the randomization visit to 96 week visit
Hospital/clinic visits with the home-based care group versus standard hospital/clinic-based care group
Hospital/clinic visits for DME or DR is the principal secondary outcome.
Time frame: from the randomization visit to 96 week visit
Proportion of study eyes with at least 5, 10 and 15 letter gains or losses in visual acuity
Proportion of study eyes with at least 5, 10 and 15 letter gains or losses in visual acuity from the randomization visit to 96 week visit. Distribution of visual acuity outcomes (20/20 or better; 20/25 or better; 20/40 or better; 20/80 or better; 20/200 or better) will also be described.
Time frame: from the randomization visit to 96 week visit
Change in OCT central subfield thickness
OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.
Time frame: from the randomization visit to 96 week visit
Change in OCT retinal volume
OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.
Time frame: from the randomization visit to 96 week visit
Long lapses in care
Lapse in care will be defined as more than 2 weeks past the target date for a visit that is scheduled either 4 or 8 weeks after a completed visit or more than 4 weeks past the target date for a visit scheduled 16 or more weeks after a completed visit. Detailed definition is provided in the protocol.
Time frame: from the randomization visit to 96 week visit
Ability to Work and Perform Regular Activities
The Work Productivity and Activity Impairment Questionnaire Global Health (WPAI-GH, Simplified Chinese version) will be used to evaluate the ability to work and perform regular activities. The WPAI-GH is a validated survey tool that consists of 6 questions assessing the impact of health problems on work performance and on regular daily activities outside of work.
Time frame: from the randomization visit to 96 week visit
Economic analysis (Cost-utility ratio)
Costs and Utilities will be calculated over the duration of the trial. The incremental cost-utility ratio (ICUR) will be calculated by taking the incremental cost of the home-based care model over the hospital/clinic-based care model and dividing them by the incremental utilities of home-based care model over hospital/clinic-based care model. A probabilistic sensitivity analysis will be conducted to better characterize overall uncertainty in the results. Details are provided in the statistical analysis protocol (SAP).
Time frame: from the randomization visit to 96 week visit
Change in best-corrected visual acuity (letter score) in the non-study eyes from the randomization visit to 96 week visit
The randomization visit is defined as the visit of the 5th loading dose. Best-corrected visual acuity (letter score) will be measured by masked optometrists using the ETDRS tumbling-E eye chart. The testing procedures are detailed in the study protocol. Data in the non-study eyes will be analyzed.
Time frame: From the randomization visit to 96 week visit
Change in best-corrected visual acuity (letter score) in the study eyes from the randomization visit to 48 week visit
The randomization visit is defined as the visit of the 5th loading dose. Best-corrected visual acuity (letter score) will be measured by masked optometrists using the ETDRS tumbling-E eye chart. The testing procedures are detailed in the study protocol. Proportion of study eyes with at least 5, 10 and 15 letter gains or losses in visual acuity, distribution of visual acuity outcomes (20/20 or better; 20/25 or better; 20/40 or better; 20/80 or better; 20/200 or better) from the randomization visit to 48 week visit will also be described.
Time frame: From the randomization visit to 48 week visit
Change in OCT retinal volume from the randomization visit to 48 week visit
OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.
Time frame: from the randomization visit to 48 week visit
Change in OCT central subfield thickness from the randomization visit to 48 week visit
OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.
Time frame: from the randomization visit to 48 week visit
Long lapses in care from the randomization visit to 48 week visit
Lapse in care will be defined as more than 2 weeks past the target date for a visit that is scheduled either 4 or 8 weeks after a completed visit or more than 4 weeks past the target date for a visit scheduled 16 or more weeks after a completed visit. Detailed definition is provided in the protocol.
Time frame: from the randomization visit to 48 week visit
Ability to Work and Perform Regular Activities from the randomization visit to 48 week visit
The Work Productivity and Activity Impairment Questionnaire Global Health (WPAI-GH, Simplified Chinese version) will be used to evaluate the ability to work and perform regular activities. The WPAI-GH is a validated survey tool that consists of 6 questions assessing the impact of health problems on work performance and on regular daily activities outside of work.
Time frame: from the randomization visit to 48 week visit
Change in superficial capillary vessel density (SVD) in the study eyes
The vessel density of the superfcial capillary plexus level will be analyzed in the 3x3 mm OCTA scanning mode (Zeiss Cirrus HD-OCT).
Time frame: Baseline, 4, 8, 12, 16 (randomization), 24, 48, 72, 96 week visit
Change in deep capillary vessel density (DVD) in the study eyes
The vessel density of the deep capillary plexus level will be analyzed in the 3x3 mm OCTA scanning mode (Zeiss Cirrus HD-OCT).
Time frame: Baseline, 4, 8, 12, 16 (randomization), 24, 48, 72, 96 week visit
Change in foveal avascular zone (FAZ) in the study eyes
The area of foveal avascular zone will be analyzed in the 3x3 mm OCTA scanning mode (Zeiss Cirrus HD-OCT).
Time frame: Baseline, 4, 8, 12, 16 (randomization), 24, 48, 72, 96 week visit
Change in non-perfusion (NP) in the study eyes
The NP regions in the superficial and deep capillary plexus were will be evaluated on the 3x3 mm OCTA Image.
Time frame: Baseline, 4, 8, 12, 16 (randomization), 24, 48, 72, 96 week visit
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.
Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 30 months is below that.
Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongshan Ophthalmic Center, Sun Yat-sen University →